Actavis Inc: (NYSE: ACT)

$121.68

1.16 (0.96%)

Volume 3,719,908

May 14 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		119.53 - 126.33
	
		52wk Low - High
		67.67 - 126.33
	
		Previous Close
		120.52
	
		Avg. Volume
		1,834,341
	
		Industry
		MED-GENERIC DRG
	
		Market Cap
		15.41 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.36
	
		PE (Forward)
		14.52
	
		Current Year Est.
		8.30
	
		Quarterly Earnings ESP 
		1.01%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		221 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            14.52
                        
                            PEG Ratio
                            1.15
                        
                            Current Year Est.
                            8.30
                        
                            Current Quarter Estimate
                            1.99
                        
                            Most Accurate Estimate
                            2.01
                        
                            Earnings ESP 
                            1.01%
                        
                            Next Earnings Report Date
                            07-25-2013
                        
                            EPS Last Year
                            6.35
                        
                            Expected Earnings Growth
                            12.62%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Actavis Inc. is a pharmaceutical company. The Company operates in three segments: Global Generics, Global Brands and Distribution. The Global Generics segment is engaged in the development, manufacturing and sale of generic pharmaceutical products. The Global Brands segment promotes and co-promotes Rapaflo, Gelnique, Trelstar, Androderm, Crinone, ella, INFeD, Generess, sodium ferric gluconate, AndroGel, and Femring branded products. The Distribution segment distributes generic and select brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines. Actavis Inc., formerly known as Watson Pharmaceuticals Inc., is headquartered in Parsippany, New Jersey.   
Full ACT Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ACT Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.99	2.09	8.30	9.28
Number of Estimates	12	12	14	15
Low Estimate	1.92	1.87	8.10	8.40
High Estimate	2.07	2.19	8.50	NA
Year Ago EPS	1.42	1.35	6.00	8.30
EPS Growth	40.43%	54.81%	38.32%	11.82%

More ACT Estimates

Average Earnings Estimates for ACT

EPS Growth for ACT

Industry Analysis

Name	Symbol	Previous Close
ACTAVIS INC	ACT	120.52
DOCTOR REDDYS	RDY	38.46
HI TECH PHARMA	HITK	32.69
IMPAX LABORATRS	IPXL	17.79
KALOBIOS PHARMA	KBIO	5.60
MYLAN INC	MYL	29.20
OMTHERA PHARMA	OMTH	7.15
SIMCERE PHARMAC	SCR	9.12
SUPERNUS PHARMA	SUPN	5.12
TEVA PHARM ADR	TEVA	39.24

Sector:Medical>> Industry:MED-GENERIC DRG

COMPARE TICKER vs. Its Peers

Zacks Commentary

Earnings Beat at Warner Chilcott

May 13, 2013

Earnings Miss at Perrigo

May 07, 2013

Perrigo Likely to Report In Line Earnings

May 06, 2013

Acorda Incurs Loss, Maintains Guidance

May 06, 2013

Company News for May 3, 2013

May 03, 2013

Actavis Beats on Earnings, Raises View

May 02, 2013

The Zacks Analyst Blog Highlights: Chicago Bridge & Iron, Shire, Actavis, UCB and WuXi PharmaTech

May 02, 2013

Shire Settles Lawsuit with Actavis

May 01, 2013

More ACT Zacks Commentary

Financials

EPS TTM	6.35
Sales	5,915
Net Income	-60
Price/Earnings	18.98
Price/Book	4.25
Price/Cash Flow	11.08
Price/Sales	2.45

More ACT Financials

News

Actavis Inc's NDA for progestin-only patch accepted by the US FDA for review by 27 December 2013 - M2

May 14, 2013

Actavis Makes Announcement Under Irish Takeover Rules - Benzinga

May 14, 2013

Announcement Under Irish Takeover Rules Relevant Securities in Issue - Pr Newswire

May 14, 2013

Announcement Under Irish Takeover Rules Relevant Securities in Issue - Pr Newswire Europe

May 14, 2013

Benzinga`s M&A Chatter for Tuesday May 14, 2013 - Benzinga

May 14, 2013

Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference - Pr Newswire

May 13, 2013

Actavis reports net loss for Q1, provides guidance for 2013 - Datamonitor

May 13, 2013

Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA - Pr Newswire

May 13, 2013

See All News Stories on ACT

Broker Recommendations

Current ABR	1.71
ABR (Last Week)	1.67
# of recs in ABR	19
Average Target Price	102.87
Industry Rank by ABR	221 out of 265
Rank in Industry	1 out of 12

More ACT Broker Recommendations

Day Low - High	119.53 - 126.33
52wk Low - High	67.67 - 126.33
Previous Close	120.52
Avg. Volume	1,834,341
Industry	MED-GENERIC DRG
Market Cap	15.41 B
Div - Yield	0.00 - 0.00
Beta	0.36
PE (Forward)	14.52
Current Year Est.	8.30
Quarterly Earnings ESP	1.01%

PE (Forward)	14.52
PEG Ratio	1.15
Current Year Est.	8.30
Current Quarter Estimate	1.99
Most Accurate Estimate	2.01
Earnings ESP	1.01%
Next Earnings Report Date	07-25-2013
EPS Last Year	6.35
Expected Earnings Growth	12.62%

Username: Password:

Remember me [?]

Actavis Inc: (NYSE: ACT)

$121.68

1.16 (0.96%)

Volume 3,719,908

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-GENERIC DRG

Zacks Commentary

Financials

News

Broker Recommendations